Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. (2020)

First Author: Mahindra A
Attributed to:  Substrate Peptidomimetic Inhibitors (SPIs) of the COP9 signalosome funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/acs.jmedchem.0c00451

PubMed Identifier: 32787140

Publication URI: http://europepmc.org/abstract/MED/32787140

Type: Journal Article/Review

Volume: 63

Parent Publication: Journal of medicinal chemistry

Issue: 17

ISSN: 0022-2623